Ecoritamab SSC with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma, including patients with POD24: Updated results from EPCORE NHL-2 Meeting Abstract
| Authors: | Merryman, R. W.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; Christensen, J. H.; Wahlin, B. E.; Linton, K. M.; Wang, L.; Abbas, A.; Rana, A.; Quadri, S.; Falchi, L. |
| Abstract Title: | Ecoritamab SSC with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma, including patients with POD24: Updated results from EPCORE NHL-2 |
| Meeting Title: | 2023 Lymphoma, Leukemia and Myeloma Congress |
| Journal Title: | American Journal of Hematology |
| Volume: | 98 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Lymphoma, Leukemia and Myeloma Congress |
| Meeting Location: | 2023 Oct 18-21 |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2023-10-01 |
| Start Page: | S37 |
| End Page: | S38 |
| Language: | English |
| ACCESSION: | WOS:001098086400060 |
| PROVIDER: | wos |
| DOI: | 10.1002/ajh.27112 |
| Notes: | Meeting Abstract: P-059 -- Source: Wos |
